Drug ID:Drug186
Drug Name:MS-20
CID:146651362
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT04908644
Molecular Formula:C24H21N3O3
Molecular Weight:399.4 g/mol
Isomeric SMILES:CC1=NC(=CC=C1)OC2=CC(=CC(=C2)OC3=CC=CC(=N3)C)OC4=CC=CC(=N4)C
Synonyms:Amelenodor; Amelenodor [INN]; NX-13; NX-13 free base; 2389235-01-0; DVH35H3HDB; UNII-DVH35H3HDB; 1,3,5-Tris((6-methylpyridin-2-yl)oxy)benzene; 2,2',2''-(1,3,5-Benzenetriyltris(oxy))tris(6-methylpyridine; 2,2',2''-(Benzene-1,3,5-triyltris(oxy))tris(6-methylpyridine)
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1313 146651362 Amelenodor 79671 NLRX1 Homo sapiens (human) Activation
dt1314 146651362 Amelenodor 79671 NLRX1 Homo sapiens (human) Agonist

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT04908644 MS-20 on Patients With Ulcerative Colitis(UC) NA RECRUITING National Taiwan University Hospital Ulcerative Colitis DRUG: MS-20 oral solution|OTHER: Placebo Details
NCT04862741 Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis PHASE1 COMPLETED Landos Biopharma Inc. Ulcerative Colitis DRUG: NX-13 250mg IR|DRUG: NX-13 500mg IR|DRUG: N… Details
NCT04458805 Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers PHASE1 COMPLETED Landos Biopharma Inc. Ulcerative Colitis DRUG: NX-13 250 mg|DRUG: Placebo Details
NCT05785715 Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis PHASE2 TERMINATED AbbVie Ulcerative Colitis DRUG: NX-13 250mg|DRUG: NX-13 750mg|DRUG: NX-13 P… Details
NCT05707429 Sexual Function and Quality of Life Among Patients Suffering From Inflammatory Bowel Disease(Inactive Stage) NULL COMPLETED Assiut University Sexual Function Disturbances|Inflammatory Bowel D… OTHER: The Arabic version of The International In… Details
NCT05706038 Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse NULL COMPLETED IRCCS San Raffaele Inflammatory Bowel Diseases|Rheumatic Disorder DRUG: Adalimumab Details
NCT05687474 Baby Detect : Genomic Newborn Screening NULL COMPLETED Centre Hospitalier Universitaire de Liege Congenital Adrenal Hyperplasia|Familial Hyperinsu… None Details
NCT05668104 Jing Si Herbal Tea for Long-Coronavirus Disease(COVID) Gut-brain Interaction NA COMPLETED Buddhist Tzu Chi General Hospital Healthy Subjects|COVID-19 Pneumonia|Irritable Bow… DIETARY_SUPPLEMENT: Jing Si Herbal Tea Liquid Pac… Details
NCT05643534 Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years PHASE3 RECRUITING Ardelyx Irritable Bowel Syndrome With Constipation (IBS-C) DRUG: Tenapanor 50 MG|DRUG: Tenapanor 25 mg bid|D… Details
NCT05626023 A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease PHASE1|PHASE2 COMPLETED Jiangsu Topcel-KH Pharmaceutical Co., Ltd. Perianal Fistula|Crohn's Disease DRUG: Human TH-SC01 cell injection Details
NCT05588843 Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Sanofi Colitis Ulcerative DRUG: SAR443122|DRUG: Placebo Details
NCT05584735 Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine NULL COMPLETED University of Wisconsin, Madison Inflammatory Bowel Diseases BIOLOGICAL: Influenza vaccine|BIOLOGICAL: COVID-1… Details
NCT05573685 Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training NA COMPLETED Click Therapeutics, Inc. Rheumatoid Arthritis|Diabetic Neuropathy|Fibromya… DEVICE: DiNaMo Study App|DEVICE: Placebo App Details
NCT05542355 EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease PHASE1 TERMINATED Exeliom Biosciences Crohn Disease DRUG: EXL01|DRUG: Placebo|OTHER: SoC corticostero… Details
NCT05536440 A Study to Learn About Study Medicine Called PF-07261271 in Healthy People PHASE1 COMPLETED Pfizer Healthy DRUG: PF-07261271|DRUG: Placebo Details
NCT05528510 A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis PHASE3 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Guselkumab Dose 1|DRUG: Guselkumab Dose 2|D… Details
NCT07161297 Remimazolam for Colonoscopy in IBD Patients PHASE4 NOT_YET_RECRUITING Humanitas Clinical and Research Center IBD (Inflammatory Bowel Disease) DRUG: Intravenous remimazolam (5 mg initially, wi… Details
NCT05507931 Broccoli Sprouts for Mild Ulcerative Colitis NA COMPLETED University of Michigan Ulcerative Colitis|Ulcerative Colitis Chronic Mild DIETARY_SUPPLEMENT: 1 Serving of broccoli sprouts… Details
NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 PHASE3 COMPLETED Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT07156929 Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation NA COMPLETED University Hospital Schleswig-Holstein Respiratory Infection (for Example, Pneumonia, Br… DIETARY_SUPPLEMENT: Controlled-ileocolonic-releas… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S04 T-cell homing and retention T-cell trafficking vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab Inhibition of the interaction between α4β7 integrins on T c… Details
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations